Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2008-05-01FDA Approved: HUMALOG MIX50/50 KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humalog Mix50/50 KwikPen (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2008-05-01FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUMET (sitagliptin and metformin hydrochloride) from Merck, resulting in changes to the pr…
-
FDA approval · 2008-04-28FDA Approved: GLIMEPIRIDE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for a generic glimepiride product from Solco Healthcare U.S., LLC.
-
FDA approval · 2008-04-25FDA Approved: GLIPIZIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for glipizide, a generic oral therapy for type 2 diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2008-04-17Clinical Trial Update: Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes [NA]
The document notes the completion of a clinical trial evaluating a cognitive behavioral program to reduce anxiety in adults with type 2 diab…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-04-17FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Precision Dose, Inc.)
FDA approved Precision Dose, Inc.'s original ANDA for Metformin Hydrochloride tablets, a generic metformin product for type 2 diabetes melli…
-
CLINICAL_TRIALS trial_result · 2008-04-15Clinical Trial Update: Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients [Phase 4]
Phase 4 trial update evaluating the effect of rosuvastatin on in vivo kinetics of apoB and apoA1 in patients with type 2 diabetes mellitus u…
-
CLINICAL_TRIALS trial_result · 2008-04-11Clinical Trial Update: AI(I)DA Acarbose and the Subclinical Inflammation [Phase 3]
A Phase 3 trial of acarbose for type 2 diabetes mellitus evaluating subclinical inflammation has completed.
-
CLINICAL_TRIALS trial_result · 2008-04-07Clinical Trial Update: Early Diagnosis of Diabetes Mellitus Type 2 (DM2)
This completed clinical trial investigates early diagnosis of Type 2 diabetes mellitus and its relation to impaired blood glucose levels and…
-
CLINICAL_TRIALS trial_result · 2008-04-01Clinical Trial Update: Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients [NA]
This entry reports on a completed clinical trial evaluating how different interventions affect glycemic control in adults newly diagnosed wi…
-
CLINICAL_TRIALS trial_result · 2008-03-31Clinical Trial Update: Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes [Phase 4]
A Phase 4 clinical trial update evaluating bedtime insulin regimens in combination with oral antihyperglycemic drugs for type 2 diabetes, wi…
-
CLINICAL_TRIALS trial_result · 2008-03-28Clinical Trial Update: Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride [Phase 4]
A Phase 4 clinical trial evaluated continuous glucose monitoring in patients with type 2 diabetes inadequately controlled on metformin, asse…
-
CLINICAL_TRIALS trial_result · 2008-03-24Clinical Trial Update: The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients [Phase 4]
Phase 4 trial evaluating the effects of nateglinide and acarbose on post-prandial glucose control in type 2 diabetes mellitus; the study has…
-
FDA approval · 2008-03-20FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approval of a supplemental application for metformin hydrochloride by Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS research · 2008-03-19Clinical Trial Update: Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2 [NA]
This clinical trial from University Hospital Tuebingen studies insulin sensitivity in the brain and its role in the development of Type 2 di…
-
CLINICAL_TRIALS research · 2008-03-18Clinical Trial Update: Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device [NA]
This document reports a clinical trial update for the GlucoTrack non-invasive glucose monitoring device, evaluating its use in people with T…
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: GALLANT 22 Tesaglitazar vs. Placebo [Phase 3]
Phase 3 trial of Tesaglitazar versus placebo for type 2 diabetes was terminated.
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: GALLANT 4 Tesaglitazar vs. Glibenclamide [Phase 3]
A Phase 3 trial (GALLANT 4) comparing tesaglitazar to glibenclamide in Type 2 diabetes mellitus was terminated.
-
CLINICAL_TRIALS research · 2008-03-17Clinical Trial Update: GALLANT 7 Tesaglitazar Add-on to Sulphonylurea [Phase 3]
The Phase 3 trial of tesaglitazar added to sulfonylurea for type 2 diabetes has been terminated.
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes [Phase 3]
The GALLEX 4 long-term extension study evaluating Tesaglitazar in patients with Type 2 diabetes has been terminated (Phase 3).
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity [Phase 2]
A Phase 2 trial evaluating tesaglitazar's effects on fat metabolism and insulin sensitivity in Type 2 diabetes was terminated.
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes [Phase 3]
The GALLEX 1 long-term extension study in patients with type 2 diabetes mellitus (Phase 3) has been terminated.
-
CLINICAL_TRIALS trial_result · 2008-03-17Clinical Trial Update: G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
The G-PLUS post-treatment follow-up study (GALLANT, GALLEX, and ARMOR) sponsored by AstraZeneca has been terminated.
-
FDA approval · 2008-03-14FDA Approved: NOVOLOG — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for NovoLOG (insulin aspart) from Novo Nordisk, signaling an approved change to the product's la…
-
CLINICAL_TRIALS trial_result · 2008-03-13Clinical Trial Update: Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated adding Nateglinide to Pioglitazone in patients with Type 2 diabetes mellitus.